Cargando…
Theranostics in immuno-oncology using nanobody derivatives
Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short‐lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this...
Autores principales: | Lecocq, Quentin, De Vlaeminck, Yannick, Hanssens, Heleen, D'Huyvetter, Matthias, Raes, Geert, Goyvaerts, Cleo, Keyaerts, Marleen, Devoogdt, Nick, Breckpot, Karine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831473/ https://www.ncbi.nlm.nih.gov/pubmed/31695800 http://dx.doi.org/10.7150/thno.34941 |
Ejemplares similares
-
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
por: Lecocq, Quentin, et al.
Publicado: (2019) -
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
por: Lecocq, Quentin, et al.
Publicado: (2021) -
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
por: Ertveldt, Thomas, et al.
Publicado: (2022) -
Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
por: Bridoux, Jessica, et al.
Publicado: (2020) -
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
por: Lecocq, Quentin, et al.
Publicado: (2020)